https://www.selleckchem.com/Akt.html
Carcinogenesis risk scores for chronic hepatitis B have been proposed, but it remains unclear whether these scores during nucleoside/nucleotide analogue (NA) therapy are useful for risk assessment. In this study, we examined changes of these scores and the predictability during NA treatment. 432 patients with no history of hepatocellular carcinoma (HCC) treated with NA were enrolled. PAGE-B, modified PAGE-B (mPAGE-, and REACH-B scores were calculated at NA administration, 1 and 2 years after administration. The median follow-up duration was 5.1 ye
Aimer
Commentaire
Partagez
